PCA062 in pCAD-positive Tumors.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Head & Neck Cancer|Esophageal Cancer
Interventions: DRUG: PCA062
Sponsor: Novartis Pharmaceuticals